600750.SS SHH
China Resources Jiangzhong Pharmaceutical Co.,Ltd
1W: +0.9%
1M: -3.5%
3M: -1.1%
YTD: -10.6%
1Y: +4.7%
3Y: +35.1%
5Y: +162.3%
¥22.53 ($3.36)
+0.23 (+1.03%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$6.9B
+5.7% ▲
5Y CAGR: +6.9%
Total Liabilities
$2.2B
+6.9% ▲
5Y CAGR: +26.5%
Shareholders Equity
$4.0B
+4.1% ▲
5Y CAGR: +0.7%
Cash & Investments
$804M
-21.0% ▼
5Y CAGR: -17.3%
Total Debt
$355M
+326551.8% ▲
5Y CAGR: +312.7%
Net Debt
-$354M
+64.9% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $1.0B | $1.4B | $1.3B | $1.0B | $709M |
| Short-Term Investments | $1.7B | $1.4B | $50M | $10M | $95M |
| Cash & ST Investments | $2.8B | $2.7B | $1.4B | $1.0B | $804M |
| Net Receivables | $794M | $775M | $545M | $951M | $851M |
| Inventory | $378M | $382M | $406M | $461M | $454M |
| Other Current Assets | $115M | $148M | $63M | $22M | $1.3B |
| Total Current Assets | $4.1B | $4.0B | $2.4B | $2.5B | $3.4B |
| Property, Plant & Equip. | $1.2B | $1.5B | $1.6B | $1.7B | $1.9B |
| Goodwill & Intangibles | $437M | $421M | $443M | $439M | $476M |
| Long-Term Investments | -$1.6B | -$1.2B | $113M | $96M | $115M |
| Other Non-Current Assets | $1.8B | $1.4B | $1.6B | $1.7B | $912M |
| Total Non-Current Assets | $1.9B | $2.2B | $3.7B | $4.0B | $3.5B |
| Total Assets | $6.0B | $6.2B | $6.1B | $6.5B | $6.9B |
| — Liabilities — | |||||
| Accounts Payable | $206M | $237M | $156M | $163M | $438M |
| Short-Term Debt | $0 | $0 | $0 | $6M | $354M |
| Deferred Revenue | $300M | $349M | $0 | $0 | $0 |
| Other Current Liabilities | $988M | $1.3B | $378M | $372M | -$132M |
| Total Current Liabilities | $1.3B | $1.7B | $1.6B | $1.8B | $1.9B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $0 | $0 | $46M | $157M | $157M |
| Total Non-Current Liabilities | $99M | $91M | $67M | $265M | $272M |
| Total Liabilities | $1.4B | $1.7B | $1.7B | $2.0B | $2.2B |
| — Equity — | |||||
| Common Stock | $630M | $630M | $629M | $629M | $635M |
| Retained Earnings | $2.7B | $2.5B | $2.4B | $2.5B | $2.6B |
| Accumulated OCI | $421M | $430M | $433M | $434M | $437M |
| Total Stockholders Equity | $4.0B | $3.9B | $3.8B | $3.9B | $4.0B |
| Total Liabilities & Equity | $6.0B | $6.2B | $6.1B | $6.5B | $6.9B |
| — Key Metrics — | |||||
| Total Debt | $4M | $3M | $1M | $109K | $355M |
| Net Debt | -$1.0B | -$1.4B | -$1.3B | -$1.0B | -$354M |
| Total Investments | $159M | $175M | $113M | $106M | $115M |